Adverum reveals positive results from Phase 1 trial of ADVM-022
Category: #health  By Mateen Dalal  Date: 2019-09-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Adverum reveals positive results from Phase 1 trial of ADVM-022

The drug was well tolerated and was safe, and has shown the capacity to improve the treatment paradigm for patients with wet AMD.

Adverum Biotechnologies, Inc., a company that develops medical therapies for ocular and rare diseases, recently announced the demonstration of positive 24-week clinical data. Apparently, the data was obtained from the initial cohort of patients treated with a one-time IVT (intravitreal) dosage of ADVM-022 in the OPTIC phase 1 clinical study in wet AMD (age-related macular degeneration).

According to reliable sources, patients who participated in this cohort gained progress in retinal anatomy and vision maintenance, without the requirement of anti-VEGF rescue injections, after a one-time IVT dose of the drug.

Reportedly, these patients earlier needed numerous anti-VEGF injections to maintain functional vision and to regulate their wet AMD. Moreover, the data is slated to be presented in September, by Szilárd Kiss, M.D., retinal specialist & the presenter for the meeting, at a podium presentation during the Retina Society 2019 Annual Meeting.

Speaking on the move, Kiss said that generally people with wet AMD need repeated anti-VEGF injections to sustain vision, representing a significant treatment load which often ends in vision loss due to lack of treatment. A long-term anti-VEGF treatment would significantly fulfill the clinical need for these patients.

He added that the material frequent injections to on ADVM-022 are promising, as they successfully show that a one-time gene therapy treated by IVT injection has the capacity to improve the treatment paradigm for patients with wet AMD and offer sustained efficacy.

As for Aaron Osborne, MBBS, Chief Medical Officer, Adverum, the company is happy to declare that there was no need for the rescue injections in this cohort of patients through 24 weeks. He claims that patient earlier needed numerous injections to prevent vision loss. Morever, a single injection of ADVM-022 resulted in constant anatomical vision maintenance and advancements.

Source Credit: http://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-reports-positive-24-week-data-first

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

G42 Healthcare & AstraZeneca ink LOI to innovate in Life Science
G42 Healthcare & AstraZeneca ink LOI to innovate in Life Science
By Mateen Dalal

G42 Healthcare, an AI-powered healthcare company, has reportedly inked an LOI (Letter of Intent) with AstraZeneca, a global science-led biopharmaceutical company, with an intention to enlarge their collaboration into the diagnostics and clinical rese...

Tata Steel Purchases coal from Russia after pledging to cut business ties
Tata Steel Purchases coal from Russia after pledging to cut business ties
By Mateen Dalal

In April, Tata Steel, India’s top steel maker, had announced that all its manufacturing units in the UK, India, and Netherlands had sourced substitute raw materials supplies to end its dependency on Russia. The company further stated that the d...

Coforge, Estes Express Lines to offer next-gen solutions to T&L sector
Coforge, Estes Express Lines to offer next-gen solutions to T&L sector
By Mateen Dalal

Coforge, an Indian multinational information technology company, is reportedly planning to collaborate with Estes Express Lines, a privately owned American freight transportation provider to offer agile, next-generation solutions to the transportatio...